Addressing the Scientific Hurdles Facing Antibiotic Innovation
Despite significant investment in drug discovery programs, research avenues pursued by industry and academia over the past three decades have largely failed to produce novel antibiotic agents because of knowledge gaps in basic science. For example, infections caused by Gram-negative bacilli present a pressing unmet need, as the cell structure of Gram-negative bacteria renders the pathogens particularly resistant to antibiotics.
As major pharmaceutical companies have downsized or abandoned antibiotic research and development, the task of addressing scientific obstacles has fallen to small companies and academic laboratories, whose resources may be limited. To rejuvenate antibiotic discovery, a growing number of experts agree that action is needed to address key scientific bottlenecks and to facilitate better collaboration across the private and public sectors.
Additional Resources
MORE FROM PEW
Explore Pew’s new and improved
Fiscal 50 interactive
Your state's stats are more accessible than ever with our new and improved Fiscal 50 interactive:
- Maps, trends, and customizable charts
- 50-state rankings
- Analysis of what it all means
- Shareable graphics and downloadable data
- Proven fiscal policy strategies
Welcome to the new Fiscal 50
Key changes include:
- State pages that help you keep track of trends in your home state and provide national and regional context.
- Interactive indicator pages with highly customizable and shareable data visualizations.
- A Budget Threads feature that offers Pew’s read on the latest state fiscal news.